February 13, 2019 - Sensus Healthcare

INVESTORS

CAREERS

About
- - Company
    - About Sensus Healthcare
    - Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions.
      
      Read More
  - Patient Advocates
  - FAQ
    - - What is SRT?
        We offer a painless, safe and highly effective non-surgical skin cancer treatment that is an alternative to surgery—Superficial Radio Therapy using the SRT-100™.
        
        Go to FAQ
      - What does SRT treat?
        The SRT-100™ is an excellent treatment option for patients with the following conditions: Keloid scars, Basal cell carcinoma, Squamous cell carcinoma, Metatypical carcinoma, Cutaneous appendage carcinoma, Actinic keratosis, Kaposi’s sarcoma.
        
        Go to FAQ
      - Is SRT right for me?
        The SRT-100™ doesn’t harm surrounding or underlying healthy tissue while targeting cancer cells. The SRT-100™ provides excellent cosmetic outcomes and is a great alternative for patients with various co-morbidities.
        
        Go to FAQ
      - What should I expect?
        You should expect the same results as surgery, but with these additional benefits: No pain, No anesthesia, No cutting, No bleeding, No stitching, No scarring, No interruption of lifestyle, No reconstructive surgery
        
        Go to FAQ
      - Is the SRT-100 safe?
        The SRT-100™ is a safe and proven technology that effectively treats non-melanoma skin cancers, keloid scarring, actinic keratosis and Kaposi’s sarcoma. It is utilized by dermatologists and radiation oncologists all over the world because it delivers good patient outcomes.
        
        Go to FAQ
  - Careers
    - - Sensus – Field Service Engineer
    - View Career Opportunities
Physicians
Patients
Investors
- Corporate Governance Guidelines
- Code of Ethics and Business Conduct
Resources
Contact Us

February 13, 2019

Modern Medicine – Dr. Brian Berman discusses the problem with keloids.

Researchers found in a retrospective study of 297 surgically excised keloids with superficial radiation therapy around the excision site that only 3% recurred during an average 6-month follow-up. Read the full article here.